NCT03595917 2025-11-04
ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML
Dana-Farber Cancer Institute
Phase 1 Recruiting
Dana-Farber Cancer Institute
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center